Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients

被引：8

作者：

Bo, Jiaqi ^{[1
,4
]}

Yu, Baohua ^{[1
,2
,3
]}

Bi, Rui ^{[1
,2
,3
]}

Xu, Xiaoli ^{[1
,2
,3
]}

Cheng, Yufan ^{[1
,2
,3
]}

Tu, Xi aoyu ^{[1
,2
,3
]}

Bai, Qianming ^{[1
,2
,3
]}

Yang, Wentao ^{[1
,2
,3
]}

Shui, Ruohong ^{[1
,2
,3
,5
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China

[2] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China

[3] Fudan Univ, Inst Pathol, Shanghai, Peoples R China

[4] Tongji Univ, Tongji Hosp, Sch Med, Dept Pathol, Shanghai, Peoples R China

[5] Fudan Univ, Fudan Univ Shanghai Canc Ctr, Shanghai Med Coll, Dept Pathol, 270 Dong an Rd, Shanghai, Peoples R China

来源：

CLINICAL BREAST CANCER | 2023年 / 23卷 / 04期

关键词：

ER-low-positive; HER2-low; Clinicopathological factor; Retrospective study; RECEPTORS STATUS; CHEMOTHERAPY; EXPRESSION; ESTROGEN; TUMOR;

D O I：

10.1016/j.clbc.2023.03.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ER and HER2 status may change after neoadjuvant therapy (NAT) in breast cancers. There have been variable discordance rates of ER and HER2 status pre-and post-NAT in previous studies. Few studies have focused on conversion of ER-low and HER-low expression status after NAT. We aimed to assess the evolution in ER and HER2 status after NAT in breast cancers. Background: Few studies have focused on converting ER-low-positive and HER2-low status following neoadjuvant therapy (NAT). We aimed to assess the evolution in ER and HER2 status after NAT in breast cancer patients. Patients and Methods: Our study included 481 patients with residual invasive breast cancer after NAT. ER and HER2 status were assessed in the primary tumor and residual disease, and associations between ER and HER2 conversion and clinicopathological factors were explored. Results: In primary tumors, 305 (63.4%) cases were ER-positive (including 36 cases of ER-low-positive), 176 (36.6%) were ER-negative. In residual disease, ER status changed in 76 (15.8%) cases, of which 69 cases switched from positive to negative. ER-low-positive tumors (31/36) were the most likely to change. In primary tumors, 140 (29.1%) tumors were HER2-positive, and 341 (70.9%) were HER2-negative (including 209 cases of HER2-low and 132 cases of HER2-zero). In residual disease, 25 (5.2%) cases had HER2 conversion between positive and negative. Considering HER2-low status, 113 (23.5%) cases had HER2 conversion, mostly driven by cases switching either to or from HER2-low. ER conversion had a positive correlation with pretreatment ER status ( r = 0.25; P = .00). There was a positive correlation between HER2 conversion and HER2-targeted therapy ( r = 0.18; P = .00). Conclusion: Conversion of ER and HER2 status was observed in some breast cancer patients after NAT. Both ER-low-positive and HER2-low tumors showed high instability from the primary tumor to residual disease. ER and HER2 status should be retested in residual disease for further treatment decisions, especially in ER-low-positive and HER2-low breast cancer.

引用

页码：436 / 446

页数：11

共 37 条

[1] Chemotherapeutic agents for the treatment of metastatic breast cancer: An update [J].

Abotaleb, Mariam ;

Kubatka, Peter ;

Caprnda, Martin ;

Varghese, Elizabeth ;

Zolakova, Barbora ;

Zubor, Pavol ;

Opatrilova, Radka ;

Kruzliak, Peter ;

Stefanicka, Patrik ;

Busselberg, Dietrich .

BIOMEDICINE & PHARMACOTHERAPY, 2018, 101 :458-477

[2] Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer [J].

Ahn, Soomin ;

Kim, Hyun Jeong ;

Kim, Milim ;

Chung, Yul Ri ;

Kang, Eunyoung ;

Kim, Eun-Kyu ;

Kim, Se Hyun ;

Kim, Yu Jung ;

Kim, Jee Hyun ;

Kim, In Ah ;

Park, So Yeon .

CANCER RESEARCH AND TREATMENT, 2018, 50 (04) :1418-1432

[3] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J].

Alberro, J. A. ;

Ballester, B. ;

Deulofeu, P. ;

Fabregas, R. ;

Fraile, M. ;

Gubern, J. M. ;

Janer, J. ;

Moral, A. ;

de Pablo, J. L. ;

Penalva, G. ;

Puig, P. ;

Ramos, M. ;

Rojo, R. ;

Santesteban, P. ;

Serra, C. ;

Sola, M. ;

Solarnau, L. ;

Solsona, J. ;

Veloso, E. ;

Vidal, S. ;

Abe, O. ;

Abe, R. ;

Enomoto, K. ;

Kikuchi, K. ;

Koyama, H. ;

Masuda, H. ;

Nomura, Y. ;

Ohashi, Y. ;

Sakai, K. ;

Sugimachi, K. ;

Toi, M. ;

Tominaga, T. ;

Uchino, J. ;

Yoshida, M. ;

Coles, C. E. ;

Haybittle, J. L. ;

Moebus, V. ;

Leonard, C. F. ;

Calais, G. ;

Garaud, P. ;

Collett, V. ;

Davies, C. ;

Delmestri, A. ;

Sayer, J. ;

Harvey, V. J. ;

Holdaway, I. M. ;

Kay, R. G. ;

Mason, B. H. ;

Forbe, J. F. ;

Franci, P. A. .

LANCET ONCOLOGY, 2018, 19 (01) :27-39

[4] Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].

Allison, Kimberly H. ;

Hammond, M. Elizabeth H. ;

Dowsett, Mitchell ;

McKernin, Shannon E. ;

Carey, Lisa A. ;

Fitzgibbons, Patrick L. ;

Hayes, Daniel F. ;

Lakhani, Sunil R. ;

Chavez-MacGregor, Mariana ;

Perlmutter, Jane ;

Perou, Charles M. ;

Regan, Meredith M. ;

Rimm, David L. ;

Symmans, W. Fraser ;

Torlakovic, Emina E. ;

Varella, Leticia ;

Viale, Giuseppe ;

Weisberg, Tracey F. ;

McShane, Lisa M. ;

Wolff, Antonio C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+

[5] St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [J].

Balic, Marija ;

Thomssen, Christoph ;

Wuerstlein, Rachel ;

Gnant, Michael ;

Harbeck, Nadia .

BREAST CARE, 2019, 14 (02) :103-110

[6] Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor-positive Breast Cancer [J].

Chen, Sheng ;

Chen, Can-Ming ;

Yu, Ke-Da ;

Zhou, Ruo-Ji ;

Shao, Zhi-Ming .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (09) :3002-3011

[7] Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies [J].

Dixon, J. Michael ;

Cameron, David A. ;

Arthur, Laura M. ;

Axelrod, Deborah M. ;

Renshaw, Lorna ;

Thomas, Jeremy S. ;

Turnbull, Arran ;

Young, Oliver ;

Loman, Cynthia A. ;

Jakubowski, Debbie ;

Baehner, Frederick L. ;

Singh, Baljit .

ADVANCES IN THERAPY, 2019, 36 (04) :828-841

[8] Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist [J].

Gahlaut, Renu ;

Bennett, Aneliese ;

Fatayer, Hiba ;

Dall, Barbara J. ;

Sharma, Nisha ;

Velikova, Galina ;

Perren, Tim ;

Dodwell, David ;

Lansdown, Mark ;

Shaaban, Abeer M. .

EUROPEAN JOURNAL OF CANCER, 2016, 60 :40-48

[9] Breast Cancer-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual [J].

Giuliano, Armando E. ;

Connolly, James L. ;

Edge, Stephen B. ;

Mittendorf, Elizabeth A. ;

Rugo, Hope S. ;

Solin, Lawrence J. ;

Weaver, Donald L. ;

Winchester, David J. ;

Hortobagyi, Gabriel N. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (04) :291-303

[10]

Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]

← 1 2 3 4 →